English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background: Patients with Parkinsons disease (PD) show a dramatic increase in their brain iron content has suggested the role of iron in degeneration of dopaminergic nigrostriatal neurons in PD. Several studies have described the association of high dietary iron and PD. However, the role of iron the pathogenesis of PD is still hotly debated. Objective: The purpose of this study was to investigate the effects of L-glutamate, oxyferriscorbone (OFC) and L-Deprenyl on parkinsonian syndrome (PS) in rats. Methods: This study was performed on 244 male non-strain rats (250-270g;-10 wk old). By intranigral bilateral administration of 1-Methyl-4- phenylpyridinium ion (MPP+) (10og/2o/l into each side) and 6-hydroxydopamine (6-OHDA) (12og/3ol, Sigma, into each side) in rats was induced the dopamine deficient model of PS (DDPS) and the cholinergic model (ChPS) in rats produced by intracaudate injection of acetylc holine (5og/2ol each side ) with neostigmine (1og/1ol each side). These models were then used to investigate the effects of L-glutamate, OFC and L-Deprenyl on PS and the electric activity (EA) of the sensorimotor cortex, caudate nuclei, ventrolateral nuclei of the thalami, and substantia nigra in rats. Results: Intracaudate injection of L-glutamate (100og/3ol, into each side) enhanced bradykinesia, rigidity and produced a weak tremor in the DDPS. This effect was more pronounced in ageing (12 months) rats and in some of them, we observed orofacial dyskinesia. In the ChPS, L-glutamate enhanced tremor and bradykinesia. The single and repeated injection of OFC (5; 7; 5; 15 and 20 mg/rat, intraperitioneally, i.p.) did not produce a statistically significant change of PS in both models. L-deprenyl (5, 10 and 20 mg/kg, i.p.) dose-dependently reduced bradykinesia and rigidity in the DDPS, whereas increased tremor and failed to decrease bradykinesia and rigidity in the ChPS. Conclusion: This study indicates that glutamate aggravates PS in both models. OFC does not have any effect on PS. Deprenyl has antiparkinsonian effect in the DDPS, but not in the ChPS.

Comparison of the effect of glutamate, oxyferriscorbone and deprenyl on Parkinsonian Syndrome